From early AIDS vaccine to HIV cure research with analytical treatment interruption trials: a study participant testimonial

Author List
William Freshwater

Abstract

In this article, I would like to discuss my experience as a participant in a recent analytical treatment interruption (ATI) study at the National Institutes of Health (NIH study 16-I-0118, an exploratory, open label study of vedolizumab in participants with HIV infection undergoing an analytical treatment interruption). This is the second HIV-related study that I have taken part in, the first one being an HIV/AIDS vaccine study with Remune back in the early 1990s.

Article Category

HIV cure research

Article Type

Viewpoints

Posted Date

22-10-2019

Tables & Figures

Back to top